Immunotherapy is a revolutionary approach to treating diseases by leveraging the body’s immune system to recognize, attack, and eliminate harmful cells, pathogens, or abnormal tissues. To fully understand the immunotherapy meaning, it refers to any treatment that uses or stimulates the immune system to fight disease. Over the last decade, it has transformed the management of several cancers and has expanded into the treatment of autoimmune disorders, allergies, infectious diseases, and other chronic conditions.
Immunotherapy is an advanced medical treatment that harnesses the power of the body’s immune system to prevent, control, or eliminate diseases. To define it in simple terms: it is a treatment approach that strengthens or modifies the immune response, enabling the body to recognize and fight harmful cells more effectively, rather than directly targeting diseased cells like conventional treatments do.
In recent years, immunotherapy for cancer has revolutionized cancer treatment by offering new hope to patients with advanced or treatment-resistant cancers. It is also being used to treat autoimmune diseases, allergies, and certain infectious diseases.
The immune system consists of specialized cells, tissues, and organs that work together to protect the body from infections and abnormal cells. However, diseases such as cancer can develop mechanisms to evade immune detection. It helps overcome these barriers, allowing the immune system to identify and destroy disease-causing cells.
Key Benefits of this therapy targets diseases with greater precision Can provide long-lasting treatment responses Enhances the body’s natural defense mechanisms May be effective when traditional treatments fail Often used alongside chemotherapy, surgery, and radiation therapy
Immunotherapy is recommended when a disease is likely to respond to treatments that enhance or modify the body’s immune system. The decision to use it is highly individualized and depends on factors such as the type of disease, its stage, the patient’s overall health, previous treatments, and the presence of specific biomarkers that indicate a higher likelihood of treatment success.
In cancer care, it may be used as a first-line treatment, after other treatments have failed, or in combination with chemotherapy, radiation therapy, or surgery. For non-cancer conditions, it is often considered when conventional treatments do not provide adequate symptom control or when long-term immune regulation is needed.
Immunotherapy has become an important treatment option for many types of cancer. A doctor may recommend it in the following situations:
Patients with advanced-stage or metastatic cancer, where the disease has spread beyond its original site, may benefit from immunotherapy. In many cases, immunotherapy can help slow disease progression, shrink tumors, and improve survival outcomes.
If cancer returns after surgery, chemotherapy, radiation therapy, or targeted therapy, immunotherapy may be used as an alternative treatment approach. It can help the immune system recognize and attack cancer cells that have survived previous treatments.
Certain tumors contain biomarkers that predict a better response to this therapy. Biomarker testing helps doctors determine whether a patient is likely to benefit from treatment.
In some cases, this may be prescribed before surgery (neoadjuvant therapy), after surgery (adjuvant therapy), or as maintenance treatment to reduce the risk of recurrence.
Although immunotherapy is most widely associated with cancer treatment, it is also used to manage several non-cancerous diseases by regulating immune system activity.
Allergy immunotherapy, often administered as allergy shots or sublingual tablets, helps the immune system gradually become less sensitive to allergens such as pollen, dust mites, pet dander, and insect venom. This approach can provide long-term symptom relief and reduce dependence on allergy medications.
In autoimmune disorders, the immune system mistakenly attacks healthy tissues. Immunotherapy can help suppress or regulate these abnormal immune responses. Conditions that may benefit include: Rheumatoid arthritis Psoriasis Multiple sclerosis Inflammatory bowel disease (IBD) Lupus
Researchers are exploring immunotherapy for chronic infectious diseases such as HIV, hepatitis B, and tuberculosis. These treatments aim to strengthen the immune system’s ability to control persistent infections.
Certain immunotherapies are used to correct immune dysfunctions, enhance immune responses in immunodeficient individuals, or prevent rejection following organ transplantation.
Understanding how it works is essential to appreciating its role in modern medicine. The primary goal of this therapy is to enhance the body’s ability to identify and destroy harmful cells. To explain how it fights cancer today: cancer cells can develop strategies to hide from immune surveillance or suppress immune responses, and it counters these strategies through several mechanisms.
The primary goal of immunotherapy is to enhance the body’s ability to identify and destroy harmful cells.
Under normal circumstances, the immune system continuously monitors the body and eliminates abnormal cells. However, cancer cells can develop strategies to hide from immune surveillance or suppress immune responses.
It works through several mechanisms:
Cancer cells often disguise themselves as normal cells, making them difficult for the immune system to detect. Immunotherapy helps expose these hidden cancer cells by improving immune recognition, enabling T-cells and other immune components to identify and attack tumors more effectively.
Certain immunotherapies stimulate immune cells, particularly T-cells and natural killer (NK) cells, making them more active and aggressive against cancer. These treatments boost the body’s natural immune response, increasing its ability to locate, attack, and destroy cancerous cells. This is a core part of how this therapy fights cancer today.
The immune system uses checkpoint proteins to prevent excessive immune reactions. Cancer cells can exploit these checkpoints to avoid detection. Checkpoint inhibitors block proteins such as PD-1, PD-L1, and CTLA-4, allowing immune cells to recognize and attack tumors effectively. This is one of the most widely studied aspects of how immunotherapy works.
Monoclonal antibodies are laboratory-engineered proteins designed to target specific markers found on cancer cells. Once attached, they help the immune system identify and destroy cancer cells, block growth signals, or deliver therapeutic agents directly to tumors.
Advanced treatments like CAR-T cell therapy involve collecting a patient’s T-cells and genetically modifying them in a laboratory. These engineered cells are programmed to recognize specific cancer proteins and are then reinfused into the body to attack cancer. This represents one of the most advanced answers to how immunotherapy works at the cellular level.
The immunotherapy success rate varies depending on the type of cancer, disease stage, and biomarker profile. While there is no single immunotherapy success rate for cancer, studies have shown significant improvements in survival and long-term disease control for patients with melanoma, lung cancer, kidney cancer, and certain blood cancers. This therapy success rate for cancer is often higher in patients with favourable biomarkers such as PD-L1, MSI-H, or high TMB.
There are several types of immunotherapy available for cancer treatment. Common cancer immunotherapy types include checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, cancer vaccines, cytokine therapy, adoptive cell transfer, and oncolytic virus therapy. These drugs and medicine options are selected based on cancer type, stage, and biomarker status.
Checkpoint inhibitors are one of the most significant advancements in modern cancer treatment. The immune system naturally uses checkpoint proteins, such as PD-1, PD-L1, and CTLA-4, to prevent excessive immune reactions that could damage healthy tissues. However, cancer cells often exploit these checkpoints to hide from immune attacks.
Checkpoint inhibitor drugs block these proteins, effectively releasing the “brakes” on the immune system. This enables T-cells to recognize and destroy cancer cells more effectively.
How They Work
Common Uses
Key Advantage
Checkpoint inhibitors can produce long-lasting responses in some patients, even after treatment has ended.
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a highly personalized form of this therapy that involves modifying a patient’s own immune cells to better fight cancer.
In this process, T-cells are collected from the patient’s blood and genetically engineered in a laboratory to recognize specific proteins on cancer cells. The modified cells are then multiplied and infused back into the patient’s body, where they actively seek out and destroy cancer cells.
How It Works
Common Uses
Key Advantage
CAR-T therapy can achieve remarkable remission rates in certain blood cancers that have not responded to conventional treatments.
Monoclonal antibodies are laboratory-produced proteins designed to mimic the body’s natural antibodies. They are engineered to recognize specific proteins, known as antigens, found on the surface of cancer cells.
Once attached to their target, monoclonal antibodies can help the immune system identify and destroy cancer cells, block growth signals, or deliver drugs directly to tumors.
How They Work
Common Uses
Key Advantage
Monoclonal antibodies provide targeted treatment while minimizing harm to normal cells.
Cancer vaccines are designed to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent diseases, most cancer vaccines are therapeutic, meaning they help treat existing cancer.
These vaccines expose the immune system to cancer-specific antigens, training immune cells to identify and eliminate cancer cells more effectively.
Types of Cancer Vaccines
Therapeutic Vaccines: Used to treat existing cancers by enhancing the immune response against tumor cells.
Personalized Vaccines: Developed using unique mutations found in an individual patient’s tumor, creating a highly customized treatment approach.
Dendritic Cell Vaccines: Use specialized immune cells called dendritic cells to present cancer antigens and activate T-cells.
Key Advantage
Cancer vaccines may help the immune system continue fighting cancer even after treatment ends.
Cytokines are naturally occurring proteins that act as messengers within the immune system. They help regulate immune responses, inflammation, and communication between immune cells.
Cytokine therapy uses laboratory-made versions of these proteins to strengthen the body’s immune response against cancer.
Common Cytokines Used
How They Work
Common Uses
Key Advantage
Cytokine therapy boosts overall immune activity, helping the body mount a stronger defense against cancer.
Adoptive Cell Transfer is an advanced technique that involves collecting immune cells from a patient, enhancing their cancer-fighting abilities in a laboratory, and then reinfusing them into the body.
Unlike CAR-T therapy, ACT may use various types of immune cells, including tumor-infiltrating lymphocytes (TILs) that are naturally found within tumors.
How It Works
Key Advantage
ACT allows doctors to use a patient’s own immune cells as a powerful weapon against cancer.
Oncolytic virus therapy uses genetically modified viruses that selectively infect and destroy cancer cells while leaving healthy cells largely unaffected.
Once inside the tumor, the virus replicates and causes cancer cells to burst. This process also releases tumor antigens that stimulate the immune system to recognize and attack remaining cancer cells.
How It Works
Common Uses
Key Advantage
Oncolytic virus therapy combines direct tumor destruction with immune system activation, creating a dual mechanism of action.
In many cases, doctors combine multiple approaches or use them alongside chemotherapy, radiation therapy, or targeted therapies to achieve the best possible outcomes.
A frequently asked question is what types of cancer can be treated with immunotherapy. Current it indications include melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, Hodgkin lymphoma, liver cancer, esophageal cancer, head and neck cancers, and certain colorectal cancers. Ongoing research continues to expand its indications across additional cancer types.
Melanoma: Melanoma is one of the cancers that responds best to immunotherapy. Checkpoint inhibitors can help the immune system identify and destroy melanoma cells, significantly improving survival rates in patients with advanced or metastatic disease.
Non-Small Cell Lung Cancer (NSCLC): It is widely used in NSCLC, especially for patients with high PD-L1 expression. It may be given alone or alongside chemotherapy to improve treatment outcomes.
Small Cell Lung Cancer (SCLC): For advanced-stage SCLC, it is often combined with chemotherapy to help control disease progression and improve survival.
Leukemia: Advanced immunotherapies, particularly CAR-T cell therapy, have shown remarkable success in treating certain types of leukemia, especially when conventional treatments have failed.
Lymphoma: Immunotherapy, including checkpoint inhibitors and CAR-T therapy, is commonly used to treat Hodgkin and non-Hodgkin lymphoma, particularly in relapsed or treatment-resistant cases.
Multiple Myeloma: Patients with advanced multiple myeloma may benefit from CAR-T cell therapy and monoclonal antibody treatments that specifically target cancerous plasma cells.
Kidney Cancer: Checkpoint inhibitors are commonly used to treat advanced kidney cancer and are often combined with targeted therapies to improve effectiveness.
Bladder Cancer: Immunotherapy is an established treatment for advanced bladder cancer, especially in patients who are unable to tolerate chemotherapy or whose cancer has returned after treatment.
Esophageal Cancer: Immunotherapy may be used in advanced esophageal cancer, particularly in patients whose tumors express specific biomarkers such as PD-L1.
Gastric (Stomach) Cancer: Certain patients with advanced gastric cancer can benefit from immunotherapy, often in combination with chemotherapy.
Colorectal Cancer: Patients with MSI-H or dMMR colorectal cancer tend to respond particularly well to immunotherapy, making biomarker testing an important part of treatment planning.
Cervical Cancer: Immunotherapy is used in advanced or recurrent cervical cancer to help the immune system target cancer cells more effectively.
Endometrial Cancer: Patients with MSI-H or dMMR endometrial cancer may experience significant benefits from checkpoint inhibitor therapy.
Oral Cancer: Immunotherapy is increasingly used for advanced oral cancers, particularly when the disease has spread or recurred after treatment.
Throat Cancer: Patients with advanced throat cancer may receive it alone or in combination with chemotherapy to improve disease control and survival.
The immunotherapy treatment process varies depending on the type of therapy being used, the condition being treated, and the patient’s overall health. However, most patients follow a similar journey that includes evaluation, treatment administration, and ongoing monitoring. Understanding what to expect can help patients feel more prepared and confident throughout their treatment.
Before starting immunotherapy, the healthcare team conducts a thorough assessment to determine whether the treatment is suitable for the patient.
This evaluation typically includes:
These tests provide important baseline information and help doctors create a personalized treatment plan.
Immunotherapy can be administered in several ways depending on the specific treatment prescribed.
Intravenous (IV) Infusion
Most immunotherapy drugs are delivered through an intravenous (IV) infusion. The medication is administered directly into a vein, usually in a cancer care hospital, or outpatient clinic. Treatment sessions may last from 30 minutes to several hours and are typically scheduled every few weeks.
Oral Medications
Some immunotherapy and immune-modulating drugs are available in tablet or capsule form. These medications can be taken at home according to the treatment schedule recommended by the doctor.
Injection-Based Treatments
Certain immunotherapies are given as injections under the skin, into a muscle, or directly into a tumor. This approach allows the treatment to target specific areas while stimulating an immune response.
Regular monitoring is an essential part of immunotherapy to ensure the treatment is working effectively and to manage any side effects.
Doctors closely monitor:
The length of immunotherapy varies from patient to patient. Some individuals receive treatment for a few months, while others may continue therapy for several years. The duration depends on factors such as the type of disease, treatment goals, response to therapy, and tolerance of side effects.
Immunotherapy has transformed the treatment landscape for cancer and several other diseases by harnessing the body’s natural immune system. Compared to traditional treatments, it offers unique advantages that can lead to more effective and long-lasting outcomes.
One of the most significant benefits of immunotherapy is its ability to provide durable treatment responses. Unlike some conventional therapies that may only offer temporary disease control, immunotherapy can help the immune system continue fighting cancer even after treatment has ended. In certain patients, this can result in long-term remission lasting for years.
Immunotherapy is designed to target specific immune pathways or cancer-related markers, allowing for a more focused treatment approach. By directing the immune system toward abnormal cells while largely sparing healthy tissues, It can reduce unnecessary damage and improve treatment precision compared to many traditional cancer therapies.
The immune system has a natural ability to remember previous threats. This can strengthen this capability by training immune cells to recognize cancer cells more effectively. As a result, the immune system may continue monitoring and attacking cancer cells even after treatment is completed, helping reduce the risk of recurrence.
Immunotherapy can be effectively combined with other treatment modalities such as chemotherapy, radiation therapy, surgery, and targeted therapies. These combinations often enhance treatment effectiveness by attacking cancer through multiple mechanisms, improving response rates, slowing disease progression, and providing better overall outcomes for many patients.
Clinical studies have shown that immunotherapy can significantly improve survival outcomes in several types of cancer, including melanoma, lung cancer, kidney cancer, and lymphoma. By strengthening the body’s natural defenses against cancer, this has helped many patients live longer while also maintaining a better quality of life.
These are two of the most commonly used cancer treatments, but they work in fundamentally different ways. While chemotherapy directly attacks cancer cells, immunotherapy empowers the body’s immune system to recognize and destroy cancer cells more effectively. Understanding these differences can help patients and caregivers make informed treatment decisions.
| Feature | Immunotherapy | Chemotherapy |
| Primary Target | Immune system | Rapidly dividing cells |
| Specificity | Highly targeted | Less targeted |
| Long-Term Response | Often durable | Variable |
| Side Effects | Immune-related | Toxicity-related |
| Personalization | Biomarker-guided | Less personalized |
The primary difference between immunotherapy and chemotherapy lies in how they fight cancer. Immunotherapy works by stimulating or modifying the immune system so it can identify and attack cancer cells. Chemotherapy, on the other hand, directly destroys rapidly dividing cells, including cancer cells and some healthy cells.
Immunotherapy is generally more targeted because it focuses on specific immune pathways or biomarkers associated with cancer. This allows the immune system to selectively attack cancer cells. Chemotherapy is less selective and may affect healthy cells that divide quickly, such as those in the hair follicles, digestive tract, and bone marrow.
Combination immunotherapy refers to the use of immunotherapy alongside other cancer treatments to enhance treatment effectiveness and improve patient outcomes. While immunotherapy can be highly effective on its own, combining it with other therapies can help overcome treatment resistance, strengthen immune responses, and target cancer through multiple mechanisms simultaneously.
Today, combination strategies have become an integral part of modern cancer care and are widely used in the treatment of various cancers, including lung cancer, melanoma, kidney cancer, bladder cancer, and head and neck cancers.
Combining immunotherapy with chemotherapy is one of the most commonly used treatment approaches in oncology. Chemotherapy works by destroying rapidly dividing cancer cells, while immunotherapy helps the immune system recognize and attack remaining cancer cells.
In addition to reducing tumor burden, chemotherapy can expose tumor antigens that make cancer cells more visible to the immune system. This enhanced visibility allows immunotherapy to work more effectively, resulting in improved response rates and longer survival in many patients.
Benefits
Radiation therapy destroys cancer cells using high-energy radiation. When combined with immunotherapy, radiation may help stimulate a stronger immune response by releasing tumor-specific antigens into the bloodstream.
This phenomenon, sometimes referred to as the “abscopal effect,” can trigger immune activity not only at the site of radiation but also against tumors located elsewhere in the body. As a result, the combination may enhance the overall anti-cancer response.
Benefits
Targeted therapies are designed to block specific genetic mutations, proteins, or pathways that drive cancer growth. Combining targeted therapy with immunotherapy allows doctors to attack cancer through different mechanisms at the same time.
While targeted therapy directly interferes with cancer cell growth, immunotherapy strengthens the body’s immune response against the tumor. This combination may improve response rates and delay disease progression in selected patients.
Benefits
Cancer is a complex disease, and a single treatment approach may not always be sufficient to achieve optimal results. Combination immunotherapy strategies help address this challenge by targeting cancer from multiple angles. They can improve treatment effectiveness, overcome resistance mechanisms, and provide better long-term outcomes for many patients.
As research continues to advance, combination immunotherapy is expected to play an even greater role in personalized cancer treatment, offering new possibilities for patients with both early-stage and advanced cancers.
Before beginning immunotherapy, doctors perform a comprehensive evaluation to determine whether the treatment is appropriate, safe, and likely to be effective. These tests help assess the patient’s overall health, understand the extent of the disease, identify potential risks, and determine the likelihood of responding to immunotherapy.
The evaluation begins with a detailed review of the patient’s medical history, including current symptoms, previous treatments, existing medical conditions, medications, and family history. A physical examination is also conducted to assess the patient’s overall health and fitness for treatment.
Imaging studies help doctors determine the location, size, and extent of the disease. They also provide a baseline for monitoring treatment response over time.
Common imaging tests include:
Blood tests are essential for evaluating overall health and identifying any underlying conditions that may affect treatment.
These tests help assess:
Regular blood tests may also be performed throughout treatment to monitor for side effects and treatment response.
Biomarker testing plays a crucial role in determining whether a patient is likely to benefit from immunotherapy. Tumor tissue or blood samples are analyzed for specific biomarkers that can predict treatment effectiveness.
Common biomarkers include:
The presence of these biomarkers may help guide treatment selection and improve outcomes.
Advanced genetic and molecular testing can identify specific mutations, gene alterations, or molecular characteristics within the tumor. These insights help doctors personalize treatment plans and determine whether immunotherapy alone or in combination with other therapies is the most suitable option.
While immunotherapy has transformed the treatment of cancer and other diseases, it is not without limitations. Despite its ability to deliver remarkable and long-lasting results in some patients, several challenges can affect its effectiveness, accessibility, and overall outcomes. Understanding these challenges is important for setting realistic expectations and improving future treatment strategies.
One of the biggest challenges of immunotherapy is that not all patients respond to treatment in the same way. While some individuals experience significant tumor shrinkage or long-term remission, others may see little or no benefit. Factors such as tumor biology, immune system function, and genetic characteristics can influence how well a patient responds to immunotherapy.
Some cancers may initially respond to immunotherapy but later develop resistance. Tumors can evolve over time and adopt mechanisms that help them evade immune detection or suppress immune activity. This can reduce the effectiveness of treatment and lead to disease progression, highlighting the need for new therapeutic approaches and combination strategies.
Advanced immunotherapies, including checkpoint inhibitors and CAR-T cell therapies, can be expensive. The cost of treatment varies; it is as if one chooses the best cancer hospital, specialized testing, and long-term monitoring may create financial challenges for patients and healthcare systems, particularly in regions with limited healthcare resources.
Although biomarkers such as PD-L1, MSI-H, and Tumor Mutational Burden (TMB) help identify patients who may benefit from immunotherapy, they are not perfect predictors of treatment response. Some patients with favorable biomarkers may not respond, while others without these markers may still experience positive outcomes.
Access to immunotherapy can vary significantly depending on the country, healthcare infrastructure, regulatory approvals, and cancer type. In some regions, limited availability of advanced therapies, best cancer treatment hospital, or biomarker testing may restrict patient access to immunotherapy.
Like all cancer treatments, immunotherapy may cause side effects. Common immunotherapy side effects include fatigue, fever, chills, nausea, rash, and loss of appetite. More serious cancer immunotherapy side effects may affect the lungs, liver, thyroid, skin, digestive system, or nervous system. Patients receiving injectable therapies may also experience cancer injection side effects, including redness, swelling, or discomfort at the injection site.
Many patients experience mild to moderate side effects during immunotherapy, especially in the early stages of treatment. These may include:
Because immunotherapy stimulates immune activity, it can sometimes cause inflammation in healthy organs and tissues.
The skin is one of the most commonly affected organs during immunotherapy.
Immune activation in the gastrointestinal tract can lead to:
Immunotherapy may affect hormone-producing glands, leading to:
Inflammation of the lungs, known as pneumonitis, can occur and may cause:
The immune system may occasionally attack liver cells, resulting in:
Although less common, immunotherapy can affect the nervous system and cause:
Most immunotherapy-related side effects can be effectively managed when identified early. Regular monitoring, routine blood tests, and prompt communication with the healthcare team are essential throughout treatment. In some cases, medications such as corticosteroids or temporary treatment interruptions may be required to control immune-related complications.
Immunotherapy represents one of the most significant breakthroughs in modern medicine. By harnessing the body’s natural immune defenses, it has transformed the treatment of cancer and is opening new possibilities for managing autoimmune diseases, allergies, and infectious conditions. As research continues to advance, immunotherapy is expected to become even more personalized, effective, and accessible, offering hope to millions of patients worldwide.
Immunotherapy for cancer has transformed modern oncology by providing more targeted and personalized treatment options. From understanding the immunotherapy meaning to learning about the types of immunotherapy, immunotherapy success rate, immunotherapy side effects, immunotherapy cost in India, and the overall immunotherapy process, patients can make better-informed decisions about their treatment journey. As research continues to advance, immunotherapy is expected to play an even greater role in the future of cancer care.
Who is eligible for immunotherapy?
Eligibility depends on the type and stage of cancer, overall health, previous treatments, and biomarker test results such as PD-L1, MSI-H, dMMR, or Tumor Mutational Burden (TMB).
Is immunotherapy used only for cancer?
No. Besides immunotherapy for cancer, immunotherapy is also used for allergies, autoimmune diseases, immune deficiencies, and certain chronic infections.
What are the different types of immunotherapy?
The main types include checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, cancer vaccines, cytokine therapy, adoptive cell transfer, and oncolytic virus therapy.
What tests are required before starting immunotherapy?
Doctors may recommend blood tests, imaging scans (CT, MRI, or PET scans), biomarker testing, genetic testing, and a comprehensive medical evaluation before starting treatment.
What is PD-L1 testing and why is it important?
PD-L1 testing measures the level of PD-L1 protein on tumor cells and helps predict whether a patient is likely to respond to certain immunotherapy drugs.
What is MSI-H and how does immunotherapy work with it?
MSI-H (Microsatellite Instability-High) indicates defects in DNA repair mechanisms. Tumors with MSI-H often respond better to immunotherapy. Understanding how immunotherapy works with MSI-H tumors is a key part of immunotherapy meaning in precision oncology.
What is Tumor Mutational Burden (TMB)?
TMB measures the number of genetic mutations within a tumor. Higher TMB levels may increase the likelihood of a positive response to immunotherapy.
What is CAR-T cell therapy?
CAR-T cell therapy is an advanced immunotherapy in which a patient’s T-cells are genetically modified in a laboratory to recognize and attack cancer cells more effectively.
What is combination immunotherapy?
Combination immunotherapy involves using immunotherapy alongside chemotherapy, radiation therapy, targeted therapy, or another immunotherapy drug to enhance treatment effectiveness.
Is immunotherapy safe for elderly patients?
Many older adults can safely receive immunotherapy. However, treatment decisions depend on overall health, medical history, and potential risks versus benefits.
No rows found.
